Usage Patterns of Stop Smoking Medications in Australia, Canada, the United Kingdom, and the United States: Findings from the 2006–2008 International Tobacco Control (ITC) Four Country Survey
Open accessThe DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Abstract
Varenicline is a new prescription stop smoking medication (SSM) that has been available in the United States since August 1, 2006, in the United Kingdom and other European Union countries since December 5, 2006, in Canada since April 12, 2007, and in Australia since January 1, 2008. There are few population-based studies that have examined use rates of varenicline and other stop smoking medications. We report data from the ITC Four Country survey conducted with smokers in the US, UK, Canada, and Australia who reported an attempt to quit smoking in past year in the 2006 survey (n = 4,022 participants), 2007 (n = 3,790 participants), and 2008 surveys (n = 2,735 participants) Respondents reported use of various stop smoking medications to quit smoking at each survey wave, along with demographic and smoker characteristics. The self-reported use of any stop smoking medication has increased significantly over the 3 year period in all 4 countries, with the sharpest increase occurring in the United States. Varenicline has become the second most used stop smoking medication, behind NRT, in all 4 countries since being introduced. Between 2006 and 2008, varenicline use rates increased from 0.4% to 21.7% in the US, 0.0% to 14.8% in Canada, 0.0% to 14.5% in Australia, and 0.0% to 4.4% in the UK. In contrast, use of NRT and bupropion remained constant in each country. Males and non-whites were significantly less likely to report using any SSM, while more educated smokers were significantly more likely to use any SSM, including varenicline. Our findings suggest that the introduction of varenicline led to an increase in the number of smokers who used evidence-based treatment during their quit attempts, rather than simply gaining market share at the expense of other medications. From a public health perspective, messages regarding increased success rates among medication users and the relative safety of stop smoking medications should be disseminated widely so as to reach all smokers of all socioeconomic classifications equally.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The American Dental Hygienists Association recommends that oral health providers: Ask patients about tobacco use, Advise quitting tobacco use, and Refer to state quitlines (Ask-Advise-Refer; AAR).”
From A National Dental Practice-Based Research Network phase II, cluster-randomized clinical trial assessing nicotine replacement therapy sampling in dental settings: study protocol for the Free Samples for Health (FreSH) study (2024) · cites this paper as [9]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Treating Tobacco Use and Dependence: 2008 Update: (566222009-001)
(2009) · PsycEXTRA Dataset · doi:10.1037/e566222009-001 · Cited by 3,046 · cited 2×
“Given the number of pharmacotherapies shown to be effective in aiding smoking cessation attempts, United States Clinical Practice Guidelines recommend the use of pharmacotherapy for all smokers who want to make a quit attempt, so as long as no contraindications for medication use are present [5,7].”
BackgroundTreating Tobacco Use and Dependence
(2008) · Pediatrics · doi:10.1542/peds.2008-1627 · Cited by 2,697
Nicotine replacement therapy for smoking cessation
Stead, L. F., Perera, R., Bullen, C., Mant, D., Hartmann-Boyce, J., Cahill, K., & Lancaster, T. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000146.pub4 · Cited by 2,464 · cited 1×
“Pharmacological treatments such as nicotine replacement therapy (NRT), sustained-release bupropion, and varenicline are effective in terms of diminishing the severity of withdrawal symptoms and reducing the chance of relapse in smokers who make a quit attempt [1-4].”
BackgroundShape of the relapse curve and long-term abstinence among untreated smokers
Hughes, J. R., Keely, J., & Naud, S. (2004) · Addiction · doi:10.1111/j.1360-0443.2004.00540.x · Cited by 1,414 · cited 2×
“Pharmacological treatments such as nicotine replacement therapy (NRT), sustained-release bupropion, and varenicline are effective in terms of diminishing the severity of withdrawal symptoms and reducing the chance of relapse in smokers who make a quit attempt [1-4].”
BackgroundInfluentialNicotine replacement therapy for smoking cessation
Silagy, C., Lancaster, T., Stead, L., Mant, D., & Fowler, G. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000146.pub2 · Cited by 972
Nicotine receptor partial agonists for smoking cessation
Hey, K., Lancaster, T., & Bala, M. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103 · Cited by 861
Nicotine receptor partial agonists for smoking cessation
Cahill, K., Stead, L., & Lancaster, T. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub2 · Cited by 747
Tobacco in Australia : facts and issues 1995
Winstanley, M. H., Woodward, S. D., & Walker, N. (1995) · Medical Entomology and Zoology · Cited by 694
Cited by
Baker, T. B., Piper, M. E., Stein, J. H., Smith, S. S., Bolt, D. M., Fraser, D. L., & Fiore, M. C. (2016) · JAMA · doi:10.1001/jama.2015.19284 · Cited by 180
Carpenter, M. J. (2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.492 · Cited by 136
Long-term Nicotine Replacement Therapy: A Randomized Clinical Trial
Schnoll, R. A., Goelz, P. M., Veluz-Wilkins, A., Blazekovic, S., Powers, L., Leone, F. T., Gariti, P., Wileyto, E. P., & Hitsman, B. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.8313 · Cited by 118
Kasza, K. A., Hyland, A. J., Borland, R., McNeill, A. D., Bansal‐Travers, M., Fix, B. V., Hammond, D., Fong, G. T., & Cummings, K. M. (2013) · Addiction · doi:10.1111/j.1360-0443.2012.04009.x · Cited by 85
Self-citationCarpenter, M. J., Jardin, B. F., Burris, J. L., Mathew, A. R., Schnoll, R. A., Rigotti, N. A., & Cummings, K. M. (2013) · Drugs · doi:10.1007/s40265-013-0038-y · Cited by 76
“The availability of varenicline in 2006 appears to have led to wider usage of evidence-based treatment [10, 11], but on the whole, the use of evidence-based pharmacotherapy remains the exception rather than the norm.”
Self-citationCarpenter, M. J., Wahlquist, A. E., Dahne, J., Gray, K. M., Garrett‐Mayer, E., Cummings, K. M., Davis, R., & Egan, B. M. (2020) · Addiction · doi:10.1111/add.14953 · Cited by 50
“Despite availability of several well-established pharmacotherapies (4, 5), a number of studies consistently show their underuse at the population level (6, 7).”
BackgroundSelf-citationGravely, S. M. L., Cummings, K. M., Hammond, D. G., Borland, R., McNeill, A. D., East, K. A., Loewen, R., Martin, N., Yong, H., Li, L., et al. (2021) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntab068 · Cited by 43
“Interestingly, it appears that the prevalence of pharmacotherapy use (NRT and OPT) for a quit attempt has remained stable (about 40%) across the four countries since 2008.(20) Few respondents used other forms of services and support.”
BackgroundSelf-citationFernández, M. E., Schlechter, C. R., Fiol, G. D., Gibson, B., Kawamoto, K., Siaperas, T., Pruhs, A., Greene, T., Nahum-Shani, I. B., Schulthies, S., et al. (2020) · Implementation Science · doi:10.1186/s13012-020-0967-2 · Cited by 35
“Although 70% of current tobacco users want to quit and over 50% attempt to quit each year [10], over 90% of those quit attempts fail, in large part because the majority (80%) fail to utilize any form of evidence-based treatment [7, 11, 12].”
BackgroundGetsios, D., Marton, J. P., Revankar, N., Ward, A. J., Willke, R. J., Rublee, D. A., Ishak, K. J., & Xenakis, J. G. (2013) · PharmacoEconomics · doi:10.1007/s40273-013-0070-5 · Cited by 28
Kasza, K. A., Cummings, K. M., Carpenter, M. J., Cornelius, M. E., Hyland, A. J., & Fong, G. T. (2014) · Addiction · doi:10.1111/add.12778 · Cited by 23
“Although early data from the International Tobacco Control Four Country Survey showed an initial spike in use of SSMs in the United States following the introduction of varenicline to the market [14], there have been no large-scale, US-specific studies evaluating trends in use of SSMs in multiple years preceding and f…”
BackgroundSelf-citationThomas, D., Briggs, V. L., Couzos, S., Panaretto, K. S., Sterren, A. E., Stevens, M., & Borland, R. (2015) · The Medical Journal of Australia · doi:10.5694/mja15.00205 · Cited by 24
Self-citationChen, B., Silvestri, G. A., Dahne, J., Lee, K., & Carpenter, M. J. (2022) · Journal of General Internal Medicine · doi:10.1007/s11606-021-07335-x · Cited by 23
History and Correlates of Smoking Cessation Behaviors Among Smokers With Serious Mental Illness
Lubitz, S. F., Flitter, A., Wileyto, E. P., Ziedonis, D. M., Stevens, N., Leone, F. T., Mandell, D. S., Kimberly, J. R., Beidas, R. S., & Schnoll, R. A. (2019) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntz229 · Cited by 20
Is a cancer diagnosis a teachable moment for the patient’s relative who smokes?
Schnoll, R. A., Wileyto, E. P., Leone, F. T., Langer, C. J., Lackman, R. D., & Evans, T. L. (2013) · Cancer Causes & Control · doi:10.1007/s10552-013-0212-2 · Cited by 22
“smoking cessation treatment program actually enroll in the program [4, 5].”
Herbeć, A., Tombor, I., Shahab, L., & West, R. (2018) · International Journal of Behavioral Medicine · doi:10.1007/s12529-018-9735-y · Cited by 20
Zhu, S., Cummins, S. E., Gamst, A. C., Wong, S., & Ikeda, T. (2015) · Tobacco Control · doi:10.1136/tobaccocontrol-2015-052332 · Cited by 17
Carpenter, M. J., Gray, K. M., Wahlquist, A. E., Cropsey, K. L., Saladin, M. E., Froeliger, B., Smith, T. T., Toll, B. A., & Dahne, J. (2020) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntaa241 · Cited by 15
“Eligibility was contingent upon: (1) age 18+; (2) daily smoker (25+ days/month); (3) smoking 5+ cigarettes/day; (4) smoking ≥1 year; (5) some eventual interest in quitting smoking (≥2 on 0–10 motivation ladder); (6) having a primary care doctor, seen ≥1 visit in past year; (7) not currently pregnant, breastfeeding, or…”
BackgroundChoi, S. K. Y., Tran, D. T., Kemp, A., Preen, D. B., Randall, D., Einarsdóttir, K., Jorm, L. R., & Havard, A. (2021) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntab063 · Cited by 15
Dahne, J., Wahlquist, A. E., Garrett-Mayer, E. S., Heckman, B. W., Cummings, K. M., & Carpenter, M. J. (2017) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntx192 · Cited by 16
Self-citationVogt, F., & Marteau, T. M. (2011) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntr197 · Cited by 10
Nagelhout, G. E., Hummel, K., Willemsen, M. C., Siahpush, M., Kunst, A. E., de Vries, H., Fong, G. T., & van den Putte, B. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2014.04.012 · Cited by 10
“Use of cessation medications was measured by asking respondents whether hey used any nicotine replacement therapy or prescription medications in the past ear (Fix et al., 2011; Borland et al., 2012).”
Self-citationDahne, J., Wahlquist, A. E., Garrett-Mayer, E. S., Heckman, B. W., Cummings, K. M., & Carpenter, M. J. (2017) · Preventive Medicine · doi:10.1016/j.ypmed.2017.10.001 · Cited by 10
“For example, use of cessation treatment increased from 22% in 2000 to only 31% in 2015 (Cokkinides et al., 2005; Fix et al., 2011; Fiore et al., 1990; Babb et al., 2017).”
BackgroundSelf-citationFang, P., Adkins-Hempel, M., Lischka, T., Basile, S., Rindal, D. B., Carpenter, M. J., Kopycka-Kedzierawski, D. T., Dahne, J., Helseth, S. A., Levy, D. E., et al. (2024) · BMC Oral Health · doi:10.1186/s12903-024-04758-w · Cited by 3
“Despite the evidence of effectiveness, tobacco cessation treatments are rarely delivered in the oral health domain [8].”
BackgroundINDIVIDUALIZED VERSUS POPULATION‐BASED APPROACHES TO TOBACCO CONTROL – A FALSE DICHOTOMY
Cummings, K. M., & Borland, R. (2011) · Addiction · doi:10.1111/j.1360-0443.2011.03531.x · Cited by 3
Self-citationLong-Term Results of Smoking Cessation Therapy
Öztuna, F., Çan, G., Ayık, S., Özlü, T., & Yılmaz, İ. (2013) · Turkiye Klinikleri Journal of Medical Sciences · doi:10.5336/medsci.2012-31326 · Cited by 1
Nam, A., Naimark, D. M. J., Stanbrook, M. B., & Krahn, M. D. (2019) · MDM Policy & Practice · doi:10.1177/2381468319852358 · Cited by 1
Bauer, A., Leone, F. T., Rogers, T., Wollack, C., Stevens, N., Purnell, J., Quinn, M. H., An, M., Jenssen, B. P., & Schnoll, R. A. (2021) · Drug and Alcohol Dependence Reports · doi:10.1016/j.dadr.2021.100006 · Cited by 1
Investigating the Drivers of Smoking Cessation: A Role of Alternative Nicotine Delivery Systems?Preprint
Hampsher, S., & Prieger, J. E. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3773201 · Cited by 4
Langley, T. E. (2012) · Nottingham ePrints (University of Nottingham)
Beliefs In Effectiveness Of Various Smoking Cessation Interventions Among Jordanian Adult Smokers
Abughosh, S., Hawari, F. I., Essien, E. J., Peters, R. J., & Wu, I. H. (2013) · Value in Health · doi:10.1016/j.jval.2013.03.1206
“A study conducted in four countries, Australia, Canada, the United Kingdom, and the United States, also found that better educated smokers were more likely to use pharmacologic methods [31].”
BackgroundNovel Strategies to Promote Smoking Cessation
Carpenter, M. J. (2016) · Journal of the South Carolina Academy of Science
- Self-citation
Hummel (2017) · Research Publications (Maastricht University) · doi:10.26481/dis.20170913kh · Cited by 1
Nam, A. (2020) · TSpace (University of Toronto)
Predictors of a Successful Outcome among Adult Smokers using Smoking Cessation Medication
Wang, X., Chen, H., Essien, E. J., Yang, M., & Abughsoh, S. (2016) · Journal of Behavioral Health · doi:10.5455/jbh.20161107025953
“, possibly due to the definition of use rate [16].”
BackgroundResultInfluential
Metadata
- Authors
- Fix, B. V., Hyland, A., Rivard, C., McNeill, A., Fong, G. T., Borland, R., Hammond, D., & Cummings, K. M.
- Affiliations
- Roswell Park Comprehensive Cancer Center (US)
- University of Nottingham (GB)
- Ontario Institute for Cancer Research (CA)
- Cancer Council Victoria (AU)
- University of Waterloo (CA)
- Corresponding author
- Fix, Brian V.
- ORCID
- Venue
- International Journal of Environmental Research and Public Health
- Publisher
- MDPI AG
- Published
- 2011-01-20
- Volume
- 8
- Issue
- 1
- Pages
- 222-233
- ISSN
- 1660-4601 (ISSN-L)
- PMC
- PMC3037071
- OpenAlex
- W2134235121
- Cited by
- 35
- References
- 29
- Citations by year
- 2024: 1 · 2022: 1 · 2021: 4 · 2020: 4 · 2019: 2 · 2018: 1 · 2017: 3 · 2016: 3 · 2015: 3 · 2014: 2 · 2013: 6 · 2012: 2
- FWCI
- 2.84
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Environmental Research and Public Health (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Portal (King's College London) (publishedVersion, other-oa)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Funders
- Cancer Research UK (450110, 014578, C312/A3726, 265903, 57897, 045734)
- Canadian Institutes of Health Research (C312/A3726, 014578, 265903, 045734, 79551, 450110, 57897)
- Medical Research Council
- Economic and Social Research Council (ES/G007489/1)
- National Health and Medical Research Council (014578, 450110, 045734, 57897, 265903, C312/A3726)
- National Cancer Institute (450110, C312/A3726, 045734, 57897, P01CA138389, 265903, R01CA100362, P50-CA111326, R01CA125116, 014578, P30CA016056)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Keywords
- varenicline, nicotine replacement therapy, bupropion, smoking cessation, drug use trends, evidence-based treatment, Australia, Canada, United Kingdom, United States
- MeSH terms
- Varenicline, Adult, Age Factors, Australia, Benzazepines, Canada, Cross-Sectional Studies, Cross-Cultural Comparison, Drug Utilization, Female, United Kingdom, Health Surveys, Humans, International Cooperation, Male, Prospective Studies, Quinoxalines, Sex Factors, Socioeconomic Factors, United States, Cohort Studies, Smoking Cessation, Nicotinic Agonists, Self Report
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.